logo

For the Inventor, By the Inventor

San Mateo, CA, United States of America

Bharat B Aggarwal

This inventor holds 8 USPTO granted patents. Top assignee: Genentech, Inc.. Active years: 1987-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bharat B Aggarwal. Retrieved from https://idiyas.com/inventor/bharat-b-aggarwal-uixklynw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 5

Forward Citations = 458(Granted Patents)


Company Filing History:

goldMedal8 out of 3,302 
 
Genentech, Inc.
 patents

Years Active: 1987-2004

Loading Chart...
8 patents (USPTO):Explore Patents
1. 6686455 - Tumor necrosis factor (2004-02-03),
2. 6177543 - Recombinant lymphotoxin (2001-01-23),
3. 5824509 - Recombinant lymphotoxin cDNA and variants (1998-10-20),
4. 5795967 - Tumor necrosis factor antagonists and their use (1998-08-18),
5. 5683688 - Unglycosylated recombinant human lymphotoxin polypeptides and (1997-11-04),
6. 5672347 - Tumor necrosis factor antagonists and their use (1997-09-30),
7. 4920196 - Human lymphotoxin (1990-04-24),
8. 4650674 - Synergistic cytotoxic composition (1987-03-17),

Title: Bharat B Aggarwal: Innovator in Biotherapeutics

Introduction

Bharat B Aggarwal is a prominent inventor based in San Mateo, CA (US). He has made significant contributions to the field of biotherapeutics, holding a total of 8 patents. His work focuses on the development of therapeutic proteins that have the potential to revolutionize cancer treatment.

Latest Patents

Among his latest patents is the identification of tumor necrosis factor, a cytotoxic protein that is recovered in a substantially homogeneous form through treatment with hydrophobic substances and ion exchange resins. This protein is conclusively identified by its amino acid sequences, and therapeutic compositions are provided. Another notable patent involves recombinant lymphotoxin, where biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. This innovation includes novel nucleic acids and vectors, enabling the economical preparation of compositions containing uniform lymphotoxin polypeptides and variants with differing amino acid sequences. The lymphotoxins are purified to a specific activity of 2-10×10 units/mg of protein using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.

Career Highlights

Bharat B Aggarwal is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has positioned him as a key figure in advancing therapeutic solutions for complex diseases.

Collaborations

Throughout his career, Aggarwal has collaborated with notable professionals in the field, including Glenn E Nedwin and Patrick W Gray. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Bharat B Aggarwal's contributions to biotherapeutics through his patents and work at Genentech, Inc. highlight his role as a leading inventor in the field. His innovative approaches to cancer treatment continue to pave the way for future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…